Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2
Authors
Keywords
-
Journal
npj Vaccines
Volume 6, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-05-13
DOI
10.1038/s41541-021-00336-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine
- (2021) Tom Shimabukuro et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial
- (2021) Raches Ella et al. LANCET INFECTIOUS DISEASES
- Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
- (2021) Jerald Sadoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
- (2021) Merryn Voysey et al. LANCET
- Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
- (2021) Denis Y Logunov et al. LANCET
- Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial
- (2021) Peter Richmond et al. LANCET
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
- (2021) Zhiwei Wu et al. LANCET INFECTIOUS DISEASES
- Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial
- (2021) Raches Ella et al. LANCET INFECTIOUS DISEASES
- A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine
- (2021) Laurence Chu et al. VACCINE
- WHO International Standard for anti-SARS-CoV-2 immunoglobulin
- (2021) Paul A Kristiansen et al. LANCET
- Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination
- (2021) Kate-Lynn Muir et al. NEW ENGLAND JOURNAL OF MEDICINE
- Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
- (2021) Nina H. Schultz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
- (2021) Andreas Greinacher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Xiaozhang Tie Improves Intestinal Motility in Rats With Cirrhotic Ascites by Regulating the Stem Cell Factor/c-kit Pathway in Interstitial Cells of Cajal
- (2020) Qiang Zhao et al. Frontiers in Pharmacology
- Eosinophil responses during COVID-19 infections and coronavirus vaccination
- (2020) Andrew W. Lindsley et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
- (2020) Feng-Cai Zhu et al. LANCET
- What policy makers need to know about COVID-19 protective immunity
- (2020) Daniel M Altmann et al. LANCET
- Middle East respiratory syndrome
- (2020) Ziad A Memish et al. LANCET
- Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial
- (2020) Till Koch et al. LANCET INFECTIOUS DISEASES
- Development of an inactivated vaccine candidate for SARS-CoV-2
- (2020) Qiang Gao et al. SCIENCE
- Consensus Summary Report for CEPI/BC March 12-13, 2020 Meeting: Assessment of Risk of Disease Enhancement with COVID-19 Vaccines
- (2020) Paul-Henri Lambert et al. VACCINE
- Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2
- (2020) Hui Wang et al. CELL
- A Thermostable mRNA Vaccine against COVID-19
- (2020) Na-Na Zhang et al. CELL
- Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes
- (2020) Shengli Xia et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
- (2020) Feng-Cai Zhu et al. LANCET
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
- (2020) Pedro M Folegatti et al. LANCET
- A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity
- (2020) Jingyun Yang et al. NATURE
- Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques
- (2020) Noe B. Mercado et al. NATURE
- ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
- (2020) Neeltje van Doremalen et al. NATURE
- Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults
- (2020) Mark J. Mulligan et al. NATURE
- Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates
- (2020) Wenlin Ren et al. VACCINE
- Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
- (2020) Denis Y Logunov et al. LANCET
- Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
- (2020) Shengli Xia et al. LANCET INFECTIOUS DISEASES
- COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
- (2020) Ugur Sahin et al. NATURE
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
- (2020) Edward E. Walsh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
- (2020) Evan J. Anderson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
- (2020) Cheryl Keech et al. NEW ENGLAND JOURNAL OF MEDICINE
- NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge
- (2020) Mimi Guebre-Xabier et al. VACCINE
- An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques
- (2020) Liqiang Feng et al. Nature Communications
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
- (2020) Merryn Voysey et al. LANCET
- Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
- (2020) Maheshi N Ramasamy et al. LANCET
- A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate
- (2020) Lorena Sanchez-Felipe et al. NATURE
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- Maintaining Safety with SARS-CoV-2 Vaccines
- (2020) Mariana C. Castells et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
- (2020) Yanjun Zhang et al. LANCET INFECTIOUS DISEASES
- Middle East Respiratory Syndrome Vaccine Candidates: Cautious Optimism
- (2019) Craig Schindewolf et al. Viruses-Basel
- Efficacy of an Adjuvanted Middle East Respiratory Syndrome Coronavirus Spike Protein Vaccine in Dromedary Camels and Alpacas
- (2019) Danielle Adney et al. Viruses-Basel
- Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Infection, Immunological Response, and Vaccine Development
- (2019) Ayman Mubarak et al. Journal of Immunology Research
- Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial
- (2019) Kayvon Modjarrad et al. LANCET INFECTIOUS DISEASES
- A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime – MVA85A boost in healthy UK adults
- (2019) Morven Wilkie et al. VACCINE
- A recombinant VSV-vectored MERS-CoV vaccine induces neutralizing antibody and T cell responses in rhesus monkeys after single dose immunization
- (2018) Renqiang Liu et al. ANTIVIRAL RESEARCH
- Ebola vaccine development: Systematic review of pre-clinical and clinical studies, and meta-analysis of determinants of antibody response variability after vaccination
- (2018) Lise Gross et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults
- (2018) L. Coughlan et al. EBioMedicine
- SARS and MERS: recent insights into emerging coronaviruses
- (2016) Emmie de Wit et al. NATURE REVIEWS MICROBIOLOGY
- A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA
- (2016) Katie Ewer et al. NEW ENGLAND JOURNAL OF MEDICINE
- MERS-CoV virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques
- (2016) Chong Wang et al. Oncotarget
- Design, recruitment, and microbiological considerations in human challenge studies
- (2015) Thomas C Darton et al. LANCET INFECTIOUS DISEASES
- A synthetic consensus anti–spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates
- (2015) Karuppiah Muthumani et al. Science Translational Medicine
- Recombinant Receptor Binding Domain Protein Induces Partial Protective Immunity in Rhesus Macaques Against Middle East Respiratory Syndrome Coronavirus Challenge
- (2015) Jiaming Lan et al. EBioMedicine
- Pre-existing immunity against Ad vectors
- (2014) Hugues Fausther-Bovendo et al. Human Vaccines & Immunotherapeutics
- Neutralizing antibody responses to enterovirus and adenovirus in healthy adults in China
- (2014) Xiang Wang et al. Emerging Microbes & Infections
- From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses
- (2013) Rolf Hilgenfeld et al. ANTIVIRAL RESEARCH
- Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus
- (2012) Chien-Te Tseng et al. PLoS One
- SARS vaccines: where are we?
- (2009) Rachel L Roper et al. Expert Review of Vaccines
- A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial
- (2008) Julie E. Martin et al. VACCINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started